US · NPCE · MEDICAL - DEVICES
NeuroPace, Inc. (NPCE) intrinsic value and stock valuation
$7.95as of 2026-11-21 · Mkt cap 467.08M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
NeuroPace, Inc. DCF and intrinsic value
InvestorsCraft values NPCE with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from NPCE’s statements →
NeuroPace, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- BrainsWay Ltd. (BWAY) $8.48
- Cerus Corporation (CERS) $1.85
- Delcath Systems, Inc. (DCTH) $18.79
- 908 Devices Inc. (MASS) $8.67
- Sight Sciences, Inc. (SGHT) $10.18
- RxSight, Inc. (RXST) $4.47
- Senseonics Holdings, Inc. (SENS) $8.02
- CVRx, Inc. (CVRX) $0.50
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $100M | $79.9M | $65.4M | $45.5M | $45.2M |
| Operating income | -$-16.34M | -$-21.67M | -$-27.17M | -$-40.79M | -$-23.74M |
| Net income | -$-21.46M | -$-27.14M | -$-32.96M | -$-47.08M | -$-36.08M |
| EPSd | -$-655.87K | -$-931.69K | -$-1.28M | -$-1.91M | -$-2.17M |
| Operating cash flow | -$-11.01M | -$-17.95M | -$-19.7M | -$-36.87M | -$-24.58M |
| Capital expenditure | -$-330K | -$-310K | -$-170K | -$-600K | -$-380K |
| Free cash flow | -$-11.34M | -$-18.25M | -$-19.87M | -$-37.47M | -$-24.96M |
| Total assets | $105.6M | $94.7M | $107.7M | $114.1M | $133.6M |
| Total debt | $70.8M | $73.3M | $72.4M | $69.8M | $49.9M |
| Net debt | $49.2M | $59.9M | $54.3M | $63.2M | $30.7M |
| Total equity | $19M | $8.01M | $20.7M | $34.8M | $73.5M |
| Cash and short-term investments | $61.1M | $52.8M | $66.5M | $77.4M | $115.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $100M | $79.9M | $65.4M | $45.5M | $45.2M |
| Cost of revenue | $22.8M | $20.8M | $17.3M | $13M | $11.8M |
| Gross profit | $77.2M | $59.1M | $48.1M | $32.5M | $33.4M |
| Research and development expenses | $27.9M | $23.7M | $20.8M | $22M | $18.2M |
| Selling, general and administrative expenses | $65.7M | $57.1M | $54.5M | $51.3M | $39M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $93.6M | $80.8M | $75.3M | $73.3M | $57.2M |
| Cost and expenses | $116.3M | $101.6M | $92.6M | $86.3M | $68.9M |
| Interest income | $2.82M | $3.02M | $3.05M | $1.58M | $450K |
| Interest expense | $7.46M | $8.8M | $8.52M | $7.53M | $7.41M |
| Depreciation and amortization | $1.95M | $1.77M | $1.6M | $2.99M | $300K |
| Ebitda | -$-12.06M | -$-16.57M | -$-22.83M | -$-36.57M | -$-28.37M |
| Operating income | -$-16.34M | -$-21.67M | -$-27.17M | -$-40.79M | -$-23.74M |
| Total other income/expenses, net | -$-5.13M | -$-5.47M | -$-5.78M | -$-6.29M | -$-12.34M |
| Income before tax | -$-21.46M | -$-27.14M | -$-32.96M | -$-47.08M | -$-36.08M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-21.46M | -$-27.14M | -$-32.96M | -$-47.08M | -$-36.08M |
| Weighted average shares outstanding | $32.7M | $29.1M | $25.9M | $24.6M | $16.6M |
| Weighted average diluted shares outstanding | $32.7M | $29.1M | $25.9M | $24.6M | $16.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $61.1M | $52.8M | $66.5M | $77.4M | $115.6M |
| Net receivables | $14.7M | $12.9M | $12.3M | $7.48M | $7.09M |
| Inventory | $16.9M | $13.4M | $11.2M | $9.71M | $7.82M |
| Total current assets | $94.1M | $81.3M | $92.7M | $97.7M | $132.8M |
| Property, plant and equipment, net | $11.3M | $12.9M | $14.4M | $15.9M | $600K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $11.5M | $13.3M | $14.9M | $16.4M | $750K |
| Total assets | $105.6M | $94.7M | $107.7M | $114.1M | $133.6M |
| Accounts payable | $2.22M | $2.95M | $2.33M | $2.15M | $1.38M |
| Short-term debt | $2.12M | $1.86M | $1.63M | $1.42M | $0.00 |
| Deferred revenue | $140K | $560K | $1.09M | $0.00 | $0.00 |
| Total current liabilities | $17.8M | $15.2M | $16.2M | $11M | $9.3M |
| Long-term debt | $68.7M | $71.5M | $70.8M | $68.4M | $49.9M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $68.7M | $71.5M | $70.8M | $68.4M | $50.8M |
| Capital lease obligations | $9.84M | $13.8M | $15.4M | $16.9M | $0.00 |
| Total liabilities | $86.5M | $86.6M | $87M | $79.3M | $60.1M |
| Common stock | $30K | $30K | $30K | $30K | $20K |
| Retained earnings | -$-552.41M | -$-530.95M | -$-503.81M | -$-470.85M | -$-423.77M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | -$-1.11M | -$-270K |
| Total equity | $19M | $8.01M | $20.7M | $34.8M | $73.5M |
| Total investments | $39.4M | $39.3M | $48.4M | $70.8M | $96.4M |
| Total debt | $70.8M | $73.3M | $72.4M | $69.8M | $49.9M |
| Net debt | $49.2M | $59.9M | $54.3M | $63.2M | $30.7M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-21.46M | -$-27.14M | -$-32.96M | -$-47.08M | -$-36.08M |
| Depreciation and amortization | $1.95M | $1.77M | $1.6M | $2.99M | $300K |
| Stock-based compensation | $11.1M | $10.3M | $9.56M | $8.35M | $4.29M |
| Change in working capital | -$-4.01M | -$-5.45M | -$-2.48M | -$-4.79M | $370K |
| Accounts receivable | -$-1.83M | -$-540K | -$-4.85M | -$-390K | $1.3M |
| Inventory | -$-3.67M | $250K | -$-1.7M | -$-2.13M | -$-1.16M |
| Accounts payable | -$-730K | $670K | $240K | $650K | $480K |
| Net cash provided by operating activities | -$-11.01M | -$-17.95M | -$-19.7M | -$-36.87M | -$-24.58M |
| Investments in property, plant and equipment | -$-330K | -$-310K | -$-170K | -$-600K | -$-380K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-330K | $8.99M | $23M | $23.8M | -$-85.4M |
| Common stock issued | $71.8M | $3.28M | $7.89M | $0.00 | $109.1M |
| Common stock repurchased | -$-49.55M | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $19.6M | $4.33M | $8.13M | $490K | $102.5M |
| Net change in cash | $8.26M | -$-4.63M | $11.5M | -$-12.58M | -$-7.45M |
| Cash at end of period | $21.8M | $13.6M | $18.2M | $6.73M | $19.3M |
| Operating cash flow | -$-11.01M | -$-17.95M | -$-19.7M | -$-36.87M | -$-24.58M |
| Capital expenditure | -$-330K | -$-310K | -$-170K | -$-600K | -$-380K |
| Free cash flow | -$-11.34M | -$-18.25M | -$-19.87M | -$-37.47M | -$-24.96M |
Line items
Line items
Line items
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
- CEO
- Joel D. Becker
- Employees
- 209
- Beta
- 1.89
Explore
Frequently asked questions
What is the intrinsic value of NeuroPace, Inc. (NPCE)?
NeuroPace, Inc. (NPCE) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is NPCE undervalued?
NPCE trades at a price of $7.95 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.